Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Evolent Health, Inc.NYSE: EVH
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 32.7% from a year ago
Cash & equivalents stood at $166.01M at the end of Q1 FY2026, down 32.7% from a year earlier and up 9.3% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.
Context
- Cash & equivalents amounted to 8.8% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -32.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 151.86M USD
- Year-over-year change
- +45.7%
- 4-year CAGR
- -13.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 151.86M | +45.7% |
| FY2024 | 2024-12-31 | 104.2M | -46.0% |
| FY2023 | 2023-12-31 | 192.83M | +2.5% |
| FY2022 | 2022-12-31 | 188.2M | -29.3% |
| FY2021 | 2021-12-31 | 266.28M | — |
Cash & Equivalents vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's Mar 2026 cash & equivalents of $166.01M is the 3rd highest of the 11 companies compared; the peer median is $98.27M.
- Its year-over-year change of -32.7% is the 10th highest of 11, against a peer median of +5.6%.
- Cash & equivalents amounts to 8.8% of total assets for EVH, versus a peer median of 21.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $560.74M | +905.3% | -19.3% | 21.5% | |
| Mar 2026 | $207.35M | +144.7% | +75.6% | 21.7% | |
| Mar 2026 | $166.01M | -32.7% | -6.9% | 8.8% | |
| Mar 2026 | $137.95M | -11.1% | -2.5% | 48.2% | |
| Mar 2026 | $124.4M | +35.5% | +38.0% | 18.5% | |
| Dec 2025 | $122.95M | -28.6% | +1.6% | 36.9% | |
| Mar 2026 | $73.59M | +3.7% | +11.7% | 22.6% | |
| Mar 2026 | $71.54M | +7.5% | -17.1% | 29.2% | |
| Mar 2026 | $62.1M | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $48.71M | -37.0% | -7.7% | 9.2% | |
| Mar 2026 | $39.08M | -23.8% | +42.2% | 6.0% | |
| Peer median (excluding EVH) | $98.27M | +5.6% | -0.5% | 21.6% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 266.28M | 188.2M | 192.83M | 104.2M | 151.86M |
| Short-term Investments | 0 | 0 | 0 | 59.3M | 0 |
| Net Receivables | 130.6M | 254.68M | 446.75M | 414.68M | 323.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 75.69M | 35.17M | 44.1M | 28.94M | 31.12M |
| Total Current Assets | 523.96M | 478.05M | 683.67M | 607.12M | 506.37M |
| Property, Plant & Equipment (Net) | 131.57M | 136.9M | 90.18M | 79.29M | 85.16M |
| Goodwill | 426.3M | 722.77M | 1.12B | 1.14B | 694.48M |
| Intangible Assets | 279.78M | 442.78M | 752.01M | 680.16M | 584.94M |
| Long-term Investments | 5.46M | 4.48M | 4.9M | 8.59M | 8.97M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 52.39M | 32.31M | 33.01M | 31.95M | 19.32M |
| Total Non-current Assets | 895.5M | 1.34B | 2B | 1.94B | 1.39B |
| Total Assets | 1.42B | 1.82B | 2.68B | 2.54B | 1.9B |
| Account Payables | 96.08M | 57.17M | 48.25M | 96.03M | 59.78M |
| Short-term Debt | 0 | 0 | 0 | 171.47M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.94M | 5.76M | 5.98M | 2.51M | 1.2M |
| Other Current Liabilities | 223.16M | 252.19M | 460.43M | 352.42M | 243.18M |
| Total Current Liabilities | 445.49M | 433.44M | 674.24M | 715.5M | 385.26M |
| Long-term Debt | 215.68M | 412.99M | 597.05M | 490.52M | 970.54M |
| Deferred Tax Liabilities | 1.4M | 50.69M | 121.24M | 119.01M | 7.51M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 110K |
| Other Non-current Liabilities | 5.53M | 4.74M | 182.06M | 193.16M | 116.81M |
| Total Non-current Liabilities | 280.33M | 524.43M | 938.37M | 827.65M | 1.1B |
| Total Liabilities | 725.83M | 957.88M | 1.61B | 1.54B | 1.48B |
| Common Stock | 908K | 1.02M | 1.15M | 1.17M | 1.18M |
| Retained Earnings | (626.78M) | (606.15M) | (719.19M) | (780.82M) | (1.32B) |
| Accumulated OCI | (362K) | (1.18M) | (1.26M) | (1.75M) | (2.62M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 693.63M | 859.42M | 1.07B | 1B | 415.19M |
| Total Debt | 280.47M | 476.12M | 644.8M | 713.67M | 989.7M |
| Net Debt | 14.19M | 287.92M | 451.97M | 609.47M | 837.84M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.